About US
Contact us
-
As end of New York opioid trial nears, AbbVie's Allergan ponies up $200M to settle its part of the caseOn the day of closing arguments in a high-profile New York opioid trial, AbbVie has inked a $200 million settlement to put the case to bed. AbbVie's Allergan has agreed to pay New York state $200 mil2021/12/8
-
Pfizer, BioNTech say omicron partially evades its COVID vaccine but booster can restore protectionThe COVID-19 vaccine produced by Pfizer and BioNTech, Comirnaty, provides less protection against the omicron variant than it did against wild-type COVID and other variants, the companiessaidon Wedne2021/12/8
-
Pfizer, ex-employee reach a deal in COVID-19 vaccine trade secrets caseA now-former Pfizer employee is playing nice after the drugmaker sued her in November alleging the 15-year veteran uploaded more than 12,000 sensitive files—including documents on the company's wildl2021/12/6
-
Call for nominations: The Most Influential People in BiopharmaIn the two years since SARS-CoV-2 first emerged, biopharmaceutical companies have taken center stage in the global fight against the pandemic. Going forward, the industry appears poised to retain its2021/12/6
-
Amgen stalls Samsung's Enbrel biosim until 2029 in 2nd patent win of the yearAmgen breathed a sigh of relief this summer when the Supreme Court declined to take up a Sandoz patent dispute challenging its anti-inflammatory blockbuster Enbrel. Now, the California drugmaker has2021/12/2
-
Merck's COVID-19 antiviral narrowly clears FDA panel—but committee echos support for revoking nod in favor of superior optionMerck and Ridgeback’s recent report that its antiviral molnupiravir wasn’t nearly as effective as previously indicated put a damper on enthusiasm that agame-changing oral treatment for COVID-19 was n2021/12/2
-
Biogen takes another blow as appeal for Tecfidera patent revival falls shortDespite Biogen's best efforts, Tecfidera generics are here to stay, it seems. A U.S. appeals court has declined to resurrect a key patent on Biogen’s once-stalwart multiple sclerosis med Tecfidera, a2021/11/30
-
After flunking key trial, Deciphera cuts 140 jobs, halts development of two drugsA devastating trial flop for Deciphera's gastrointestinal cancer drug Qinlock has prompted the company to undergo a painful transformation. On Tuesday, the Massachusetts biopharmasaidit will cut 1402021/11/30
-
GSK's ViiV looks to future of injectable HIV treatment as long-acting PrEP decision loomsThe future of ViiV Healthcare's HIV business is injectable. By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around£2 billion ($2.65 bill2021/11/26
-
Bristol Myers Squibb's next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutinyAfter the FDA slapped an updated safety warning on marketed oral JAK inhibitors for inflammatory diseases, market watchers have started worrying about other candidates in the pipeline. Bristol Myers2021/11/26